Inloggad som:

avslutad_INDUCE-3

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
avslutad_INDUCE-3
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 2-3
Palliativ
Företag

Studien ändrades senast av: studysonia (2022-05-03)

Tillbaka till listan